affiliate disclosure · we earn commission on some vendor links. audits, scores, and rankings are independent — vendors do not pay for placement. read more →
Peptide research & literature
Sara writes the peptide guides, the mechanism explainers, and the research-literature reviews. Her background is in pharmacology research — eight years at a contract research organization running preclinical pharmacokinetics work before moving into science writing full-time. She reads the primary research literature so vialaudit readers don't have to, and she's the person on the desk who decides which peptide is mature enough for a guide. If a compound only has rodent data, she says so. If a Phase 2 trial is being misrepresented in community discussion, she writes the literature read. Sara writes under a pen name. The peptide research-protocol space attracts strong opinions and direct outreach to authors; she'd rather keep the email volume manageable and the work honest.
Peptide guides, mechanism explainers, primary-literature reviews, pharmacokinetics summaries, dose-research literature, trial result reads.
A research read on the peptides currently studied for longevity outcomes - rapamycin, NAD+, MOTS-c, GHK-Cu, Klotho, epitalon, GHRH analogs, and the rest. Which have human evidence, which have only model-organism data, and what each actually does at the mechanism level.
KLOW is a four-component peptide stack growing fast in research-protocol discussion. Here's the literature read - what each compound does, what the mechanism overlap argues, and what's actually been studied as a combination.
BPC-157 and TB-500 are the most-stacked combination in research-peptide protocols. The compounds work through different mechanisms — angiogenesis vs actin sequestration — which is why the combination is studied. Here's the literature read.
Phase 2 tested 1, 4, 8 and 12 mg weekly. Phase 3 TRIUMPH narrowed to 4, 9 and 12 mg. Full step-up chart, what each arm produced, and the mL/unit math. Investigational, not medical advice.
GI events (nausea ~50% at high dose, vomiting, diarrhea) plus a 1–3 bpm heart-rate signal attributed to glucagon-receptor activity — the literature read of side-effect frequencies from the published Phase 2 and TRIUMPH Phase 3 retatrutide trials, with the cardiovascular outcomes question still pending as of August 2026.
TRIUMPH-4 through TRIUMPH-3 have now reported: up to 28.7% weight loss in knee osteoarthritis, 28.3% in obesity, 20.8% with type 2 diabetes, 22.6% in established cardiovascular disease. Lilly plans to file the BLA in Q1 2027.
Tips, corrections, or comments on research desk coverage: research@vialaudit.com